Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
contract-liabilities-chart

PFE Current Contract Liabilities

Current Contract LiabilitiesCurrent Contract Liabilities

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) Current Contract Liabilities in Q1'26 shows a value of $0 USD, indicating no reported liabilities at the end of this period. This marks a complete depletion from the previous quarter's $784M USD in Q4'25, covering the timeframe from Q2'23 to Q1'26. Overall, the chart reveals an initial growth phase from $1.29B USD in Q2'23 to a peak of $2.70B USD in Q4'23, followed by moderate stability around $2.5B USD through Q2'24, and then a sharp, sustained decline to $784M USD by Q4'25, culminating in zero liabilities in Q1'26. This downward trend suggests accelerating recognition of deferred revenue or reduced new contract commitments, with notable drops exceeding 25% quarter-over-quarter in Q3'24 and beyond, potentially signaling improved cash flow conversion but warranting scrutiny on future contract inflows.